Understanding the implications of co-delivering therapeutic agents in a nanocarrier to combat multidrug resistance (MDR) in breast cancer
Authors:
- Aditi D. FulfagerAFAditi D. Fulfager
- Khushwant S. YadavKYKhushwant S. Yadav
- 1 April 2021
- journal article
- review article
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 62
Abstract
No abstract availableKeywords
This publication has 102 references indexed in Scilit:
- Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly(β-amino esters)Biomaterials, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- The microenvironment in breast cancer progression: biology and implications for treatmentBreast Cancer Research, 2011
- Doxorubicin-Tethered Responsive Gold Nanoparticles Facilitate Intracellular Drug Delivery for Overcoming Multidrug Resistance in Cancer CellsACS Nano, 2011
- The molecular and cellular biology of lung cancer: identifying novel therapeutic strategiesBritish Medical Bulletin, 2010
- ABC transporters in cancer: more than just drug efflux pumpsNature Reviews Cancer, 2010
- A Novel Docetaxel-Loaded Poly (ε-Caprolactone)/Pluronic F68 Nanoparticle Overcoming Multidrug Resistance for Breast Cancer TreatmentDiscover Nano, 2009
- Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles☆Advanced Drug Delivery Reviews, 2007
- Solid lipid nanoparticles as drug delivery systemsMethods and Findings in Experimental and Clinical Pharmacology, 2005
- Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the artEuropean Journal of Pharmaceutics and Biopharmaceutics, 2000